(A) Agilent Technologies - Ratings and Ratios
Spectrometers, Chromatography, Diagnostics, Services, Consumables
Dividends
| Dividend Yield | 0.89% |
| Yield on Cost 5y | 1.11% |
| Yield CAGR 5y | 15.35% |
| Payout Consistency | 67.2% |
| Payout Ratio | 17.9% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 29.0% |
| Value at Risk 5%th | 44.3% |
| Relative Tail Risk | -6.97% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.02 |
| Alpha | -15.54 |
| CAGR/Max DD | -0.04 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.427 |
| Beta | 1.027 |
| Beta Downside | 1.003 |
| Drawdowns 3y | |
|---|---|
| Max DD | 36.55% |
| Mean DD | 16.60% |
| Median DD | 15.83% |
Description: A Agilent Technologies December 03, 2025
Agilent Technologies (NYSE:A) delivers application-focused analytical solutions across three operating segments: Life Sciences & Applied Markets, Diagnostics & Genomics, and Agilent CrossLab services. The core segment supplies a broad portfolio of chromatography, mass-spectrometry, spectroscopy, and laboratory automation instruments, together with consumables such as columns and reagents. The Diagnostics & Genomics unit adds genomics platforms, pathology tools, and cell-analysis systems, while CrossLab monetizes after-sale services-including repairs, SaaS analytics, and compliance consulting-through direct and indirect sales channels.
Based on Agilent’s FY2023 filing, total revenue was approximately **$6.5 billion**, with the Life Sciences & Applied Markets segment contributing about **57 %** of sales and posting an operating margin near **23 %**. R&D intensity averaged **13 %** of revenue, reflecting continued investment in next-generation mass-spectrometry and AI-driven data analytics. The company’s cash conversion cycle has tightened to roughly **45 days**, indicating efficient working-capital management.
Key macro drivers for Agilent include the **global surge in biotech venture capital** (U.S. biotech VC funding hit a record $30 billion in 2023) and the expanding **precision-medicine market**, projected to exceed **$100 billion** by 2028. Regulatory pressure for higher analytical fidelity in drug development and environmental testing also underpins demand for Agilent’s high-resolution instruments. Conversely, a slowdown in discretionary capital spending could pressure the CrossLab services pipeline.
If you’re looking for a deeper, data-centric view of Agilent’s valuation dynamics, a quick scan of the company’s profile on ValueRay can surface the most recent analyst metrics and scenario analyses.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (1.30b TTM) > 0 and > 6% of Revenue (6% = 416.9m TTM) |
| FCFTA 0.12 (>2.0%) and ΔFCFTA -0.07pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 32.34% (prev 31.71%; Δ 0.64pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 1.56b > Net Income 1.30b (YES >=105%, WARN >=100%) |
| Net Debt (1.56b) to EBITDA (1.83b) ratio: 0.85 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.96 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (284.0m) change vs 12m ago -2.41% (target <= -2.0% for YES) |
| Gross Margin 52.43% (prev 54.30%; Δ -1.87pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 56.55% (prev 54.96%; Δ 1.59pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 13.81 (EBITDA TTM 1.83b / Interest Expense TTM 112.0m) >= 6 (WARN >= 3) |
Altman Z'' 2.56
| (A) 0.18 = (Total Current Assets 4.59b - Total Current Liabilities 2.35b) / Total Assets 12.73b |
| (B) 0.11 = Retained Earnings (Balance) 1.39b / Total Assets 12.73b |
| (C) 0.13 = EBIT TTM 1.55b / Avg Total Assets 12.29b |
| (D) 0.19 = Book Value of Equity 1.17b / Total Liabilities 5.99b |
| Total Rating: 2.56 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 75.80
| 1. Piotroski 6.50pt |
| 2. FCF Yield 3.47% |
| 3. FCF Margin 21.10% |
| 4. Debt/Equity 0.50 |
| 5. Debt/Ebitda 0.85 |
| 6. ROIC - WACC (= 6.71)% |
| 7. RoE 20.62% |
| 8. Rev. Trend 8.56% |
| 9. EPS Trend 44.14% |
What is the price of A shares?
Over the past week, the price has changed by -3.99%, over one month by -7.81%, over three months by +13.57% and over the past year by -0.07%.
Is A a buy, sell or hold?
- Strong Buy: 9
- Buy: 2
- Hold: 9
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the A price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 169.4 | 21.3% |
| Analysts Target Price | 169.4 | 21.3% |
| ValueRay Target Price | 141 | 0.9% |
A Fundamental Data Overview December 12, 2025
P/E Trailing = 31.3939
P/E Forward = 23.2558
P/S = 5.854
P/B = 5.9055
P/EG = 2.193
Beta = 1.274
Revenue TTM = 6.95b USD
EBIT TTM = 1.55b USD
EBITDA TTM = 1.83b USD
Long Term Debt = 3.35b USD (from longTermDebt, two quarters ago)
Short Term Debt = 304.0m USD (from shortTermDebt, last quarter)
Debt = 3.35b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.56b USD (from netDebt column, last quarter)
Enterprise Value = 42.24b USD (40.67b + Debt 3.35b - CCE 1.79b)
Interest Coverage Ratio = 13.81 (Ebit TTM 1.55b / Interest Expense TTM 112.0m)
FCF Yield = 3.47% (FCF TTM 1.47b / Enterprise Value 42.24b)
FCF Margin = 21.10% (FCF TTM 1.47b / Revenue TTM 6.95b)
Net Margin = 18.75% (Net Income TTM 1.30b / Revenue TTM 6.95b)
Gross Margin = 52.43% ((Revenue TTM 6.95b - Cost of Revenue TTM 3.31b) / Revenue TTM)
Gross Margin QoQ = 51.80% (prev 52.59%)
Tobins Q-Ratio = 3.32 (Enterprise Value 42.24b / Total Assets 12.73b)
Interest Expense / Debt = 0.81% (Interest Expense 27.0m / Debt 3.35b)
Taxrate = 1.81% (8.00m / 442.0m)
NOPAT = 1.52b (EBIT 1.55b * (1 - 1.81%))
Current Ratio = 1.96 (Total Current Assets 4.59b / Total Current Liabilities 2.35b)
Debt / Equity = 0.50 (Debt 3.35b / totalStockholderEquity, last quarter 6.74b)
Debt / EBITDA = 0.85 (Net Debt 1.56b / EBITDA 1.83b)
Debt / FCF = 1.07 (Net Debt 1.56b / FCF TTM 1.47b)
Total Stockholder Equity = 6.32b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.24% (Net Income 1.30b / Total Assets 12.73b)
RoE = 20.62% (Net Income TTM 1.30b / Total Stockholder Equity 6.32b)
RoCE = 16.00% (EBIT 1.55b / Capital Employed (Equity 6.32b + L.T.Debt 3.35b))
RoIC = 15.82% (NOPAT 1.52b / Invested Capital 9.60b)
WACC = 9.11% (E(40.67b)/V(44.03b) * Re(9.80%) + D(3.35b)/V(44.03b) * Rd(0.81%) * (1-Tc(0.02)))
Discount Rate = 9.80% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.55%
[DCF Debug] Terminal Value 72.68% ; FCFE base≈1.43b ; Y1≈1.48b ; Y5≈1.67b
Fair Price DCF = 76.94 (DCF Value 21.78b / Shares Outstanding 283.1m; 5y FCF grow 3.28% → 3.0% )
EPS Correlation: 44.14 | EPS CAGR: 7.55% | SUE: 0.47 | # QB: 0
Revenue Correlation: 8.56 | Revenue CAGR: 2.86% | SUE: 1.10 | # QB: 3
EPS next Quarter (2026-01-31): EPS=1.37 | Chg30d=-0.054 | Revisions Net=-8 | Analysts=15
EPS current Year (2026-10-31): EPS=5.95 | Chg30d=-0.071 | Revisions Net=-12 | Growth EPS=+6.4% | Growth Revenue=+5.9%
EPS next Year (2027-10-31): EPS=6.56 | Chg30d=-0.078 | Revisions Net=-4 | Growth EPS=+10.3% | Growth Revenue=+6.2%
Additional Sources for A Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle